Disease-a-month : DM · 2026
Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Inban Pugazhendi, Agrawal Ashita, Rushika Kakarala, Tariq Halla, Thai Andy, Kudaiarov Dastan, Prajjwal Priyadarshi, John Jobby
Аннотация
BACKGROUND/OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have an exciting future potential beyond metabolic disorders. This review gauges their effectiveness, safety, and clinical role in the management of substance use disorders in diverse populations.
METHODS: A PRISMA-guided systematic review searched PubMed, Scopus, WoS, CENTRAL and PsycINFO up to March 2026; 1641 records were identified, 11 included; screening, extracting and evaluating the efficacy, safety, and bias of the studies.
RESULTS: 11 studies were selected out of 1641 records. Reduced substance-related outcomes were always observed with GLP-1RAs. In alcohol use disorder (AUD), there was a decrease in the risk of hospitalization (aHR 0.640.72), and reduced incident AUD (OR 0.260.71), but randomized controlled trials (RCTs) provided contradictory outcomes (p = 0.37; 29% reduction, p = 0.04). Semaglutide reduced the risk of tobacco use disorder (HR 0.68; 95% CI 0.630.74). There was a great decrease in the risk of opioid overdose (HR 0.32-0.58). The incidence (HR 0.86), mortality (HR 0.50), and suicidal ideation were less in composite substance use disorder (SUD) outcomes (HR 0.75). Weight reduction was consistent (-2.9 kg; ≥16 kg in 37.5%), with HbA1c improvements (-0.25%). RCTs were found to be low-bias and the observational studies were moderate-bias. The safety profiles were positive, and there were no patterns of increasing serious adverse events (SAEs).
CONCLUSION: GLP-1RAs have good potential protective properties against SUD especially in observational research with good safety. However, robust randomized trials are needed to confirm causality and clinical applicability.
METHODS: A PRISMA-guided systematic review searched PubMed, Scopus, WoS, CENTRAL and PsycINFO up to March 2026; 1641 records were identified, 11 included; screening, extracting and evaluating the efficacy, safety, and bias of the studies.
RESULTS: 11 studies were selected out of 1641 records. Reduced substance-related outcomes were always observed with GLP-1RAs. In alcohol use disorder (AUD), there was a decrease in the risk of hospitalization (aHR 0.640.72), and reduced incident AUD (OR 0.260.71), but randomized controlled trials (RCTs) provided contradictory outcomes (p = 0.37; 29% reduction, p = 0.04). Semaglutide reduced the risk of tobacco use disorder (HR 0.68; 95% CI 0.630.74). There was a great decrease in the risk of opioid overdose (HR 0.32-0.58). The incidence (HR 0.86), mortality (HR 0.50), and suicidal ideation were less in composite substance use disorder (SUD) outcomes (HR 0.75). Weight reduction was consistent (-2.9 kg; ≥16 kg in 37.5%), with HbA1c improvements (-0.25%). RCTs were found to be low-bias and the observational studies were moderate-bias. The safety profiles were positive, and there were no patterns of increasing serious adverse events (SAEs).
CONCLUSION: GLP-1RAs have good potential protective properties against SUD especially in observational research with good safety. However, robust randomized trials are needed to confirm causality and clinical applicability.